Cidara Therapeutics Inc (NASDAQ:CDTX) has been given a consensus rating of “Buy” by the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $14.28.
Several analysts have recently issued reports on CDTX shares. Cantor Fitzgerald set a $15.00 target price on Cidara Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. Zacks Investment Research lowered Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, December 25th.
Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Cidara Therapeutics during the 2nd quarter worth $131,000. OxFORD Asset Management LLP lifted its position in shares of Cidara Therapeutics by 69.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 22,181 shares of the biotechnology company’s stock worth $187,000 after buying an additional 9,065 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Cidara Therapeutics by 77.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock worth $328,000 after buying an additional 18,001 shares during the last quarter. Eversept Partners LLC bought a new stake in shares of Cidara Therapeutics during the 4th quarter worth $340,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Cidara Therapeutics during the 2nd quarter worth $650,000. Institutional investors and hedge funds own 66.95% of the company’s stock.
Cidara Therapeutics (CDTX) traded down $0.15 on Friday, hitting $8.00. The stock had a trading volume of 53,201 shares, compared to its average volume of 114,471. The firm has a market cap of $169.29, a price-to-earnings ratio of -2.54 and a beta of 1.70. Cidara Therapeutics has a 12 month low of $5.60 and a 12 month high of $8.80. The company has a current ratio of 6.43, a quick ratio of 6.43 and a debt-to-equity ratio of 0.12.
Cidara Therapeutics (NASDAQ:CDTX) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.05. equities analysts anticipate that Cidara Therapeutics will post -2.6 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Cidara Therapeutics Inc (CDTX) Receives $14.28 Average Target Price from Analysts” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/cidara-therapeutics-inc-cdtx-receives-14-28-average-target-price-from-analysts.html.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.